Sucampo Pharmaceuticals Inc. (SCMP) Trading 1.9% Higher
Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP)’s share price traded up 1.9% during mid-day trading on Monday . The company traded as high as $11.62 and last traded at $11.53, with a volume of 89,268 shares. The stock had previously closed at $11.31.
A number of equities analysts recently issued reports on the company. Mizuho reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Wednesday, May 4th. Zacks Investment Research raised Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, August 8th. Jefferies Group decreased their price objective on Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating for the company in a report on Thursday, August 4th. WallachBeth Capital raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Thursday, May 5th. Finally, Guggenheim reissued a “buy” rating and issued a $29.00 price objective on shares of Sucampo Pharmaceuticals in a report on Wednesday, May 4th. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $19.67.
The company’s 50 day moving average price is $11.56 and its 200 day moving average price is $11.51. The company has a market capitalization of $501.31 million and a P/E ratio of 41.09.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.01. The business had revenue of $52 million for the quarter, compared to the consensus estimate of $48.33 million. The firm’s revenue for the quarter was up 49.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.21 EPS. Analysts forecast that Sucampo Pharmaceuticals Inc. will post $1.02 earnings per share for the current fiscal year.
Sucampo Pharmaceuticals, Inc is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.